ARK Genomic Revolution ETF
ARKG
231 hedge funds and large institutions have $613M invested in ARK Genomic Revolution ETF in 2025 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 53 increasing their positions, 62 reducing their positions, and 21 closing their positions.
100% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 21
16% more capital invested
Capital invested by funds: $528M → $613M (+$85.7M)
8% more funds holding
Funds holding: 213 → 231 (+18)
4.85% more ownership
Funds ownership: 49.93% → 54.79% (+4.9%)
10% less call options, than puts
Call options by funds: $78.8M | Put options by funds: $87.2M
15% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 62
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$21.4M |
| 2 |
Morgan Stanley
New York
|
+$17.8M |
| 3 |
Jane Street
New York
|
+$5.83M |
| 4 |
D.E. Shaw & Co
New York
|
+$5.07M |
| 5 |
KF
Krilogy Financial
St. Louis,
Missouri
|
+$4.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$25.9M |
| 2 |
JP Morgan Chase
New York
|
-$10.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$9.64M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$7.47M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5.82M |
ARKG Hedge Fund Activity: Q3 2025 in Review
231 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q3 2025, worth a combined $613M — up 16% from $528M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new ARKG positions and 21 closed out — a net gain of 21 holders — while 53 added to existing stakes and 62 trimmed.
The largest buyer was Citigroup, adding an estimated $21.4M. The largest seller was Goldman Sachs, cutting an estimated $25.9M.
- 231 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q3 2025, up from 213 in Q2 2025.
- Funds reported $613M of ARK Genomic Revolution ETF stock for Q3 2025, up 16% quarter-over-quarter.
- 42 funds opened new ARK Genomic Revolution ETF positions in Q3 2025 and 21 closed out, a net change of +21 holders.
- The largest ARK Genomic Revolution ETF buyer in Q3 2025 was Citigroup, an estimated $21.4M added.
- The largest ARK Genomic Revolution ETF seller in Q3 2025 was Goldman Sachs, an estimated $25.9M sold.
Based on aggregated 13F filings for Q3 2025.